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Florian Szabados2, Sören Gatermann2 and Martin Kaase2Abstract
We studied the presence of extended spectrum beta lactamases (ESBLs) in 44 clinical isolates of Escherichia coli
collected from out-patients in two university teaching hospitals in South-Eastern Nigeria. Species identification was
performed by standard microbiology methods and re-confirmed by MALDI-TOF technology. Phenotypic
characterization of ESBL enzymes was done by double disc synergy test and presence of ESBL genes was
determined by specific PCR followed by sequencing. Transfer of plasmid DNA was carried out by transformation
using E. coli DH5 as recipient strain. Phenotypic characterization identified all isolates to be ESBL positive. 77% of
strains were from urine, 13.6% from vaginal swabs and 9.0% from wound swabs. 63.6% were from female patients,
68% were from outpatients and 95.5% from patients younger than 30 years. All ESBL producers were positive in a
PCR for blaCTX-M-1 cluster, in exemplary strains blaCTX-M-15 was found by sequencing. In all strains ISEcp1 was found
upstream and ORF477 downstream of blaCTX-M. PCR for blaTEM and blaOXA-1 was positive in 93.1% of strains, whereas
blaSHV was not detected, aac(6′)-Ib-cr was found in 97.7% of strains. RAPD analysis revealed seven different clonal
groups named A through G with the majority of the strains (65.9%) belonging to clone A. Transfer of an ESBL
plasmid with co-resistance to gentamicin, kanamycin, tobramycin, doxycycline and trimethropim-sulfamethoxazole
was successful in 19 (43.2%) strains. This study showed a high rate of CTX-M-1 cluster - ESBLs in South-Eastern
Nigeria and further confirms the worldwide spread of CTX-M ESBL in clinical isolates.
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Microbial resistance is a growing major public health
issue and a strong concern for the medical community.
Production of β-lactamases is a major means by which
Gram-negative bacteria exhibit resistance to β-lactam
antibiotics [1]. Extended spectrum β-lactamases (ESBLs)
are a group of enzymes that can hydrolyze a variety of
β-lactams including cephalosporins like ceftazidime,
cefotaxime, ceftriaxone and monobactams like aztreo-
nam in addition to penicillins but do not hydrolyze
cephamycins like cefoxitin. Most of the ESBLs also have* Correspondence: ifynero@yahoo.com
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reproduction in any medium, provided the orthe ability to hydrolyze fourth generation cephalosporins
like cefepime [2]. Until recently, ESBL-producing organ-
isms were viewed as hospital-acquired or health care-
associated pathogens, i. e. affecting patients who had
typically been in hospitals or other health care facilities
like nursing homes [3,4]. In the last decades however,
these infections have increasingly been recognized in
patients who had no prior contact with the health care
system [5,6]. E. coli strains producing CTX-M type
ESBLs drive this new epidemic. Reports on this newer
group of ESBLs, coined CTX-M for their preferential hy-
drolysis of cefotaxime over ceftazidime started to emerge
in E. coli in the late 1990s [7]. Studies have indicated
that the genes for CTX-M type ESBLs were mobilized
from the chromosomes of Kluvera spp. to E. coli plas-
mids through transposon-mediated events [8,9]. Cur-
rently five clusters of CTX-M type ESBLs have beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CTX-M-9, and CTX-M-25 clusters. CTX-M-14 belong-
ing to the CTX-M-9 cluster and CTX-M-15 belonging
to the CTX-M-1 cluster are particularly associated with
community-acquired isolates. In the present study, we
investigated the molecular epidemiology of clinical iso-
lates of ESBL producing Escherichia coli isolated from
outpatients in South-Eastern Nigeria.
Materials and methods
A total of 44 clinical isolates of E. coli were isolated from
patients attending University of Nigeria teaching hos-
pital, Enugu (HA, n = 28) and Ebonyi State University
teaching hospital Abakaliki (HB, n = 16). All isolates
were characterized using standard microbiology methods
and re-confirmed by MALDI-TOF [10,11]. Extended
spectrum beta lactamase enzymes were determined by
double disc synergy test (DDST) method with disks of
ceftazidime, cefotaxime, ceftriaxone, cefepime, and
aztreonam (30 μg each) placed at a distance of 15 mm
(center to center) from a disk containing amoxicillin
plus clavulanic acid (20 and 10 μg, respectively) [12].
Isolation of genomic DNA of ESBL E. Coli
Genomic DNA of ESBL E. coli was prepared using the
NucleoSpin Kit (Macherey & Nagel, Germany) following
manufacturer’s instructions.
Detection of resistance gene using PCR method
Primers used for amplification of resistance genes are
shown in Table 1. Cycling conditions were as follows:
















RAPD_1290 GTGGATGCGAcycles of denaturation at 94°C for 30 s and a final exten-
sion step at 72°C for 5 min. Annealing temperatures dif-
fered according to the primer pair used and were 42°C
for TEM, 47°C for SHV, 52°C for OXA-1, 58.8°C for
CTX-M-1. Amplified PCR products were separated on
0.8% agarose gels, stained with ethidium bromide and
visualized under UV illumination. Appropriate positive
and negative controls were used in all cases [13-15].
Some PCR products were sequenced with 3730 sequen-
cer (applied biosystem). The nucleotide and deduced
amino acid sequence were analyzed and compared to se-
quence available over the Internet at the National Center
for Biotechnology Information (http:IIwww.ncbi.nlm.
gov). A PCR with specific primers for aac(6′)-Ib-cr was
performed [16] with the primers shown in Table 1 and
an annealing temperature of 45°C and followed by re-
striction with BseGI. The genetic environment of
blaCTX-M [17] was analyzed by PCR for ISEcp1 upstream
and ORF477 downstream with the primers shown in
Table 1.
Randomly amplified polymorphic DNA (RAPD) analysis
RAPD was performed with all the 44 ESBL positive
strains using a single primer as showed in Table 1 with
annealing temperature of 37°C [18].
Transformation studies
Plasmid DNA was extracted with the Qiagen Midi Kit
PC100 (Qiagen, Germany). Transformation of plasmids
was carried out by electroporation with E. coli DH5 cells
as recipient strain at 2.5 kV, 25 F and 200 using a Gene–
Pulser (Bio-Rad, Hemel hempstead, UK). Samples fromAmplicon size Source
860 bp Schlesinger et al. [13]
776 bp Schlesinger et al. [13]
730 bp Schlesinger et al. [13]
369 bp Karisik E et al. [15]
Variable Eckert C et al. [17]
460 bp this study
this study
482 bp Park CH et al. [16]
Pacheco AB et al. [18]
Table 3 Characteristics of successful transformants
Strains Co-resistance
10 CAZ, CTX, ATM, AMP, DO SXT, W
14 CAZ, CTX, ATM, AMP, TOB, CN, SXT, K
20 CAZ, CTX, ATM, AMP, DO, C, SXT, W
29 CAZ, CTX, ATM, AMP, K, TOB, CN, SXT
43 CAZ, CTX, ATM, AMP, SXT, DO, W, CN
48 CAZ, CTX, ATM, AMP, K, TOB, CN, DO
49 CAZ, CTX, ATM, AMP, K, TOB, CN DO
50 CAZ, CTX, ATM AMP, K, TOB, CN, DO, SXT, W.
60 CAZ, CTX, ATM, AMP, K, TOB, CN, DO
65 CAZ, CTX, ATM, AMP, K, TOB, CN, DO
73 CAZ, CTX, ATM, AMP, K, TOB, CN
74 CAZ, CTX, ATM, AMP, K, TOB, CN, DO, C, SXT, W
75 CAZ, CTX, ATM, AMP, K, TOB, CN
77 CAZ, CTX, ATM, AMP, K, TOB, CN,
78 CAZ, CTX, ATM, AMP, K, TOB, CN, DO
84 CAZ, CTX, ATM, AMP, DO, SXT, W
112 CAZ, CTX, ATM, AMP, SXT, C
131 CAZ, CTX, ATM, AMP, K, TOB, CN, DO
138 CAZ, CTX, ATM, AMP, K, TOB, CN
Key: CAZ-ceftazidime, CTX- cefotaxime, ATM- aztreonam, AMP- ampicillin,
TOB- tobramycin, SXT- sulfametoxazole/trimethroprim, W- trimethroprim,
DO- doxycycline, CN-gentamicin, K-kanamycin, C-chloramphenicol.
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Transformants growing on the selection plates (cefotax-
ime 2 mg/L, Sigma Aldrich Poole UK) were subjected to
DDST to confirm the presence of ESBL genes and were
examined for co-transfer of other antibiotic resistance
determinants present in the donor clinical isolates by
disk diffusion.
Results
The overall result showed that of 44 E. coli strains stud-
ied 34 (77.2%) were from urine, 6 (13.6%) from vaginal
swabs and 4 (9.0%) from wound swabs, 28 (63.6%) were
from female patients. Remarkably the proportion of out-
patients was very high (68%). The majority of patients
(n = 42; 95.5%) were younger than 30 years.
All 44 E. coli strains were phenotypically confirmed as
ESBL, PCR for blaCTX-M and blaCTX-M-1 cluster was posi-
tive in all strains. Three exemplary isolates were chosen
for sequencing of the full blaCTX-M gene and sequence
analysis revealed them as blaCTX-M-15. PCRs for ISEcp1
upstream and ORF 477 downstream of blaCTX-M were
positive in all strains. PCRs for TEM and OXA-1 beta lac-
tamase genes were positive in 41 (93.1%) ESBL isolates.
SHV could not be found in any isolate (Table 2). Also the
presence of aac(6′)-Ib-cr could be demonstrated in 43
strains (97.7%) by PCR and subsequent restriction ana-
lysis. No significant difference regarding the frequency of
blaOXA-1, blaTEM and aac(6′)-Ib-cr between ESBLs from
hospital A and Hospital B could be found. RAPD analysis
of ESBL strains for clonal relatedness grouped the strains
into seven clonal groups (A-G). Clone A was by far the
most frequent clone and found in 65.9% of all studied
strains. Compared to other clones it is more frequent in
hospital B (81%) than in hospital A (57.1%). PCR results in
relation to clonal type are presented in Table 2. The asso-
ciation of CTX-M-1 cluster genes to TEM, OXA-1 and
aac(6′)-Ib-cr is stronger in Clone A ESBLs than in other
clonal types. ESBL plasmid could be successfully trans-
formed in 19 (43.2%) out of 44 ESBL E. coli. Co-resistance
to gentamicin, kanamycin, tobramycin, doxycycline and
trimethropim-sulfamethoxazole was observed in most
transformants (Table 3).Table 2 PCR results in relation to RAPD groups (n = 44)
PCR tests Clona A (n= 29) Other clones (n = 15) Total
bla
CTX-M-1 29(100%) 15(100%) 44(100%)
ISEcp1 29(100%) 15(100%) 44(100%)
ORF 477 29(100%) 15(100%) 44(100%)
bla
SHV 0(0%) 0(0%) 0(0%)
bla
TEM 26(89.7%) 15(100%) 41(93.1%)
bla
OXA-1 28(96.5%) 13(85%) 41(93.1%)
aac(6)′-Ib-cr 28(96.5%) 15(100%) 3(97.7%)Discussions
This study was carried out in two major university
teaching hospitals in South-Eastern Nigeria where there
is no record of investigation of molecular epidemiology
of ESBL E. coli. Nosocomial bacterial infections consti-
tute a substantial cause of morbidity and mortality in
developing countries such as Nigeria. E. coli is known to
be one of the major organisms causing nosocomial
infections within the hospital and has also been impli-
cated in community acquired ESBL [19,20]. The obser-
vation of ESBL producing E. coli strains in this study is
very alarming and this could be attributed to the indis-
criminate and widespread use of antibiotics, particularly
beta lactam antibiotics that are sold over the counter in
pharmacy shops without doctors’ prescription in Nigeria.
This misuse of antibiotics might have contributed to the
emergency of ESBL producing isolates. All 44 ESBL
E. coli strains harbored ESBLs of the CTX-M-1 cluster.
In three exemplary strains the CTX-M-15 ESBL could
be confirmed which belongs to the CTX-M-1 cluster.
These results further emphasize that this enzyme is now
one of the most common CTX-M β- lactamases world-
wide. In several countries CTX-M-15 is currently the
most frequent ESBL in E. coli like in the UK, India,
Spain, France, Latin America and Lebanon [20]. In
Nigeria ESBL has been described in Enterobacter spp.
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M-15 ESBL in K. pneumoniae from the same region four
years later [22] while ESBL was also reported in E. coli
from South Eastern Nigeria this same year [23] but no
description of CTX-M-15 ESBL from outpatients has
been reported. Recently CTX-M-15 ESBL producing E.
coli was reported from hospital patients in Osogbo in
Western Nigeria [24]. CTX-M-15 has also been reported
from other African countries like Egypt [25], Algeria
[26], Tunisia [27], Tanzania [28], and Cameroon [29].
One of the most alarming findings of our study is that
most ESBL isolates were detected in urine from young
outpatients; urine was the source of 81.8% of ESBL strains,
68.2% of patients were of an age below 30 years. This
strongly indicates that CTX-M-15 carrying E. coli strains
can cause community-acquired urinary tract infections
and that those ESBL strains are not only present in a hos-
pital environment but also in the community population
of this area of Nigeria. Similar observations have been
made also in other parts of the world [5,6].
Typing of isolates via RAPD grouped the isolates into
seven different clones. Seven strains could not be typed by
this method and the majority of ESBL E. coli strains studied
in this work belongs to a single clone as determined by
RAPD. Of particular interest is that this clone A was
detected in two hospitals located more that 70 km away
from each other. One possible explanation is patient-to-
patient transmission in both hospitals and introduction of
clone A into another hospital by patient transfer. Hospital
A serves as referral hospital for patients in hospital B with
serious medical problems. A certain degree of inter-
hospital spread was discovered because two patients with
clone A ESBLs were known to have visited both hospitals
during our study period. Thus, it is of high importance to
apply specific infection control measures like hand disinfec-
tion in hospitals. Considering that also clone A ESBL iso-
lates were found in young outpatients, another possible
explanation might be that clone A occurs rather frequently
in the population of this area. If so, it would be worth the
effort to exclude a possible common source like drinking
water or food products.
As observed worldwide for CTX-M-15 ESBL E. coli
strains, we found a high association of CTX-M-1 cluster
ESBLs with ISEcp1 upstream and ORF 477 downstream
of the gene, with the presence of TEM and OXA-1 beta
lactamases and with the detection of aac(6′)-Ib-cr. The
latter gene mediates resistance to tobramycin and
decreased susceptibility to ciprofloxacin [30]. Thus it is
one of several factors responsible for multi-drug resist-
ance also to non-beta lactam antibiotics in ESBL strains.
Conclusions
For the first time ESBL E. coli strains could be demon-
strated from Southeastern Nigeria with CTX-M-1cluster enzymes present in all isolates. Most of the
ESBL strains also carried TEM, OXA-1 and aac(6′)-Ib-
cr and the majority of strains were isolated from outpa-
tients below the age of 30. Based on our findings we
suggest that antimicrobial resistance surveillance net-
work be established in the two hospitals to monitor the
trends and new types of resistance mechanism in
Southeastern, Nigeria.
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